Cardio Diagnostics Holdings Inc.
As of Oct 22, 2026, Cardio Diagnostics Holdings is in Stage 1, the basing phase, now in week 4 (since Sep 30, 2026). It closed at $1.71, 74.0% below its 52-week high and below its 200-day average, which is falling.
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CDIO early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CDIO among Biotechnology403rd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …403 | CDIO | Stage 1 · wk 4 | 18 | −11.2% |
Cardio Diagnostics Holdings: quick answers
What stage is Cardio Diagnostics Holdings in?
As of Oct 22, 2026, Cardio Diagnostics Holdings (CDIO) is in Stage 1, the basing phase. It entered Stage 1 on Sep 30, 2026 and is in week 4. What the four stages mean
Is Cardio Diagnostics Holdings in an uptrend?
Not yet. Cardio Diagnostics Holdings is in Stage 1, a base that can come before an uptrend. It trades 18.1% below its 200-day average, which is falling.
How far is Cardio Diagnostics Holdings from its 52-week high?
Cardio Diagnostics Holdings closed at $1.71 on Oct 22, 2026, 74.0% below its 52-week high of $6.55. Its 52-week low is $1.05.
How has Cardio Diagnostics Holdings performed over the past year?
As of Oct 22, 2026, Cardio Diagnostics Holdings is down 60.8% over the past year and down 40.0% so far in 2026.
Which sector and industry is Cardio Diagnostics Holdings in?
Cardio Diagnostics Holdings is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.